Nuvectis Pharma (NVCT) Total Liabilities (2021 - 2026)

Nuvectis Pharma (NVCT) has 6 years of Total Liabilities data on file, last reported at $11.2 million in Q1 2026.

• For the quarter ending Q1 2026, Total Liabilities rose 21.58% year-over-year to $11.2 million; the trailing twelve-month figure through Mar 2026 stood at $11.2 million (up 21.58% YoY), and the FY2025 full-year result was $13.3 million, up 49.49% from the prior year.
• Total Liabilities fell to $11.2 million in Q1 2026, from $13.3 million in the prior quarter.
• In the past five years, Total Liabilities ranged from a high of $13.3 million in Q4 2025 to a low of $2.7 million in Q2 2022.
• A 5-year average of $7.0 million and a median of $6.2 million in 2022 frame the typical range for Total Liabilities.
• Across the five-year window, Total Liabilities surged 155.73% in 2022 and rose 12.9% in 2023, its largest moves.
• Tracing NVCT's Total Liabilities over 5 years: stood at $6.2 million in 2022, then increased by 12.9% to $7.0 million in 2023, then increased by 27.35% to $8.9 million in 2024, then jumped by 49.49% to $13.3 million in 2025, then declined by 15.93% to $11.2 million in 2026.
• Business Quant data shows NVCT's Total Liabilities at $11.2 million in Q1 2026, $13.3 million in Q4 2025, and $11.6 million in Q3 2025.